Attached files

file filename
10-K - LIGHTLAKE THERAPEUTICS, INC. 10-K - OPIANT PHARMACEUTICALS, INC.a6074458.htm
EX-3.I - EXHIBIT 3 - OPIANT PHARMACEUTICALS, INC.a6074458ex3i.htm
EX-31.2 - EXHIBIT 31.2 - OPIANT PHARMACEUTICALS, INC.a6074458ex31_2.htm
EX-10.6 - EXHIBIT 10-6 - OPIANT PHARMACEUTICALS, INC.a6074458ex10_6.htm
EX-10.7 - EXHIBIT 10-7 - OPIANT PHARMACEUTICALS, INC.a6074458ex10_7.htm
EX-31.1 - EXHIBIT 31.1 - OPIANT PHARMACEUTICALS, INC.a6074458ex31_1.htm
EX-10.5 - EXHIBIT 10-5 - OPIANT PHARMACEUTICALS, INC.a6074458ex10_5.htm
EX-10.4 - EXHIBIT 10-4 - OPIANT PHARMACEUTICALS, INC.a6074458ex10_4.htm
 
EXHIBIT 32
 

CERTIFICATION
Pursuant to 18 U.S.C. 1350
(Section 906 of the Sarbanes-Oxley Act of 2002)

In connection with the Annual Report on Form 10-K of Lightlake Therapeutics Inc. (the"Company") for the year ended July 31, 2008, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Seijin Ki, as ChiefExecutive Officer and Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002, that:

(1)  The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2)  The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

       
Date: 10/15/09
By:
/s/ Seijin Ki  
    Seijin Ki  
    Chief Executive Officer  
    Chief Financial Officer  


 
This certification accompanies each Report pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002 and shalL not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of ss.18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.